HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:

Reckitt reports personal-care growth

This article was originally published in The Rose Sheet

  • News

Executive Summary

UK-based Reckitt Benckiser says contribution of Mucinex expectorants helped drive 13% growth in its health and personal-care unit in the fourth quarter, to £567 mil. ($885.6 mil.). Division's net sales totaled $3.25 bil. for full fiscal 2009, a 14% gain, Reckitt reports. Initial sales of Lysol No-Touch Hand Soap System, which automatically dispenses antibacterial soap upon sensing the user's hand, were "very encouraging," CEO Bart Becht said during same-day analyst call. Firm plans to launch a line of Clearasil Overnight products in the first half of 2010 in multiple markets. Reckitt Benckiser booked overall revenue of $3.22 bil. in Q4, a 10% increase, and $12.11 bil. for the full year, up 8%. Adjusted earnings jumped 14% to $699.8 mil. for the quarter, and rose 13% to $2.21 bil. for the year

You may also be interested in...



On CRN Challenge, Nexus Formulas Gets Lesson On Supporting Ad Claims For Supplements

So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go its "scope of review" and note unclear instructions on Plavinol labels.

FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse

Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.
Table

View full table

Tags:
UsernamePublicRestriction

Register

RS016735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By